Patents by Inventor David Graham Tew

David Graham Tew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES
    Publication number: 20200277659
    Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.
    Type: Application
    Filed: March 30, 2020
    Publication date: September 3, 2020
    Inventors: Andreas CRAMERI, Malcolm Leithhead HILL, David Graham TEW
  • Processes for the production of oligonucleotides
    Patent number: 10640812
    Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Andreas Crameri, Malcolm Leithhead Hill, David Graham Tew
  • NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES
    Publication number: 20180023122
    Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 25, 2018
    Inventors: Andreas CRAMERI, Malcolm Leithhead Hill, Sarah Louise Lovelock, Markus Schober, David Graham Tew, Pamela Joan Thomas
  • Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy
    Publication number: 20120045774
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 23, 2012
    Applicant: Smithkline Beecham Corporation
    Inventors: Colin Houston MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 8088886
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: January 3, 2012
    Assignee: Smith-Kline Beecham P.L.C.
    Inventors: Colin Houston MacPhee, David Graham Tew
  • Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy
    Publication number: 20090136969
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 28, 2009
    Inventors: Colin Houston MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 7416853
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: August 26, 2008
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Colin H. MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 7314742
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: January 1, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 7217535
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: May 15, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Colin H. MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 7052862
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compunds to identify those compounds.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: May 30, 2006
    Assignee: SmithKline Beecham
    Inventors: Colin H. MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 7045329
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: May 16, 2006
    Assignee: SmithKline Beecham plc
    Inventors: Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Publication number: 20030186421
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Application
    Filed: April 2, 2003
    Publication date: October 2, 2003
    Inventors: Colin Houston MacPhee, David Graham Tew
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Publication number: 20030148398
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compunds to identify those compounds.
    Type: Application
    Filed: June 14, 2002
    Publication date: August 7, 2003
    Inventors: Colin H. MacPhee, David Graham Tew
  • Method of treatment
    Publication number: 20030044399
    Abstract: The present invention relates to methods of treating parasitic diseases which are mediated by cysteine proteases by administration of 4-amino-azepan-3-one protease inhibitors. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.
    Type: Application
    Filed: February 13, 2002
    Publication date: March 6, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Scott Kevin Thompson, David Graham Tew, Daniel Frank Veber
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Publication number: 20020177209
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Application
    Filed: August 3, 2001
    Publication date: November 28, 2002
    Applicant: SmithKline Beecham plc
    Inventors: Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
    Publication number: 20020156018
    Abstract: The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.
    Type: Application
    Filed: April 12, 2002
    Publication date: October 24, 2002
    Inventors: Scott Kevin Thompson, Daniel Frank Veber, Thaddeus Anthony Tomaszek, David Graham Tew
  • Phospholipase A2 inhibitors thereof and use of same in diagnosis and therapy
    Patent number: 6369045
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule incoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: April 9, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Colin Houston Macphee, David Graham Tew, Deirdre Mary Bernadette Hickey
  • Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
    Patent number: 6177257
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: January 23, 2001
    Assignee: SmithKline Beechman
    Inventors: Colin Houston Macphee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Azetidinone derivatives for the treatment of atherosclerosis
    Patent number: 6071899
    Abstract: Azetidinone derivatives of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen or C.sub.(1-8) alkyl; R.sup.3 is C.sub.(1-8) alkyl or C.sub.(3-8) cycloalkyl each of which may be optionally substituted; X is a linker group; Y is an aryl group; and n is 0, 1 or 2; and excluding benzyl (4-methylthio-2-oxo-azetidin-1-yl)acetate are inhibitors of the enzyme Lp PLA2 and are of use in therapy, in particular treating atherosclerosis.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: June 6, 2000
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Deirdre Mary Bernadette Hickey, Dashyant Dhanak, Colin Andrew Leach, Robert John Ife, David Graham Tew
  • Substituted azetidin-2-ones for treatment of atherosclerosis
    Patent number: 5990102
    Abstract: Compounds of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen, halogen or C.sub.(1-8) alkyl; R.sup.3 is aryl or aryl C.sub.(1-4) alkyl which may be optionally substituted; X is a linker group; Y is an optionally substituted aryl group; and n is 0, 1 or 2; are inhibitors of the enzyme Lp-PLA.sub.2 and thereof of use in treating atherosclerosis.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: November 23, 1999
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Deirdre Mary Bernadette Hickey, Dashyant Dhanak, Colin Andrew Leach, Robert John Ife, David Graham Tew